161 related articles for article (PubMed ID: 6261926)
21. Optimal control of cyclophosphamide-induced emesis.
Stewart A
Oncology; 1996 Jun; 53 Suppl 1():32-8. PubMed ID: 8692548
[TBL] [Abstract][Full Text] [Related]
22. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
23. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues.
Carey MP; Burish TG; Brenner DE
Ann Intern Med; 1983 Jul; 99(1):106-14. PubMed ID: 6305249
[TBL] [Abstract][Full Text] [Related]
24. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients.
Levitt M
Cancer Treat Rev; 1982 Dec; 9 Suppl B():49-53. PubMed ID: 6299556
[No Abstract] [Full Text] [Related]
25. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.
Treish I; Shord S; Valgus J; Harvey D; Nagy J; Stegal J; Lindley C
Support Care Cancer; 2003 Aug; 11(8):516-21. PubMed ID: 12836088
[TBL] [Abstract][Full Text] [Related]
26. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study.
Sweet DL; Miller NJ; Weddington W; Senay E; Sushelsky L
J Clin Pharmacol; 1981; 21(S1):70S-75S. PubMed ID: 6271845
[TBL] [Abstract][Full Text] [Related]
27. Intravenous Delta-9-Tetrahydrocannabinol to Prevent Postoperative Nausea and Vomiting: A Randomized Controlled Trial.
Kleine-Brueggeney M; Greif R; Brenneisen R; Urwyler N; Stueber F; Theiler LG
Anesth Analg; 2015 Nov; 121(5):1157-64. PubMed ID: 26426861
[TBL] [Abstract][Full Text] [Related]
28. Review of cannabinoids and their antiemetic effectiveness.
Vincent BJ; McQuiston DJ; Einhorn LH; Nagy CM; Brames MJ
Drugs; 1983 Feb; 25 Suppl 1():52-62. PubMed ID: 6301800
[TBL] [Abstract][Full Text] [Related]
29. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study.
McCallum RW; Soykan I; Sridhar KR; Ricci DA; Lange RC; Plankey MW
Aliment Pharmacol Ther; 1999 Jan; 13(1):77-80. PubMed ID: 9892882
[TBL] [Abstract][Full Text] [Related]
30. In search of an effective antiemetic: a nusring staff participates in marijuana research.
Seipp CA; Chang AE; Shiling DJ; Rosenberg SA
Cancer Nurs; 1980 Aug; 3(4):271-6. PubMed ID: 6249493
[No Abstract] [Full Text] [Related]
31. [An antiemetic effect of methylprednisolone plus droperidol against nausea and vomiting caused by administration of high-dose adriamycin to breast carcinoma patients].
Adachi K; Onodera T; Minami T; Murata N; Mashiko N; Sato T; Yazawa C
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2560-3. PubMed ID: 3619464
[TBL] [Abstract][Full Text] [Related]
32. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
Sallan SE; Cronin C; Zelen M; Zinberg NE
N Engl J Med; 1980 Jan; 302(3):135-8. PubMed ID: 6985702
[TBL] [Abstract][Full Text] [Related]
33. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
34. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
[TBL] [Abstract][Full Text] [Related]
35. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Beck TM; Ciociola AA; Jones SE; Harvey WH; Tchekmedyian NS; Chang A; Galvin D; Hart NE
Ann Intern Med; 1993 Mar; 118(6):407-13. PubMed ID: 8439113
[TBL] [Abstract][Full Text] [Related]
37. Nabilone: an alternative antiemetic for cancer chemotherapy.
Dalzell AM; Bartlett H; Lilleyman JS
Arch Dis Child; 1986 May; 61(5):502-5. PubMed ID: 3013104
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Beck TM
Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
[TBL] [Abstract][Full Text] [Related]
39. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac.
Söderpalm AH; Schuster A; de Wit H
Pharmacol Biochem Behav; 2001; 69(3-4):343-50. PubMed ID: 11509190
[TBL] [Abstract][Full Text] [Related]
40. Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates.
Wooldridge LM; Ji L; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
J Pharmacol Exp Ther; 2020 Sep; 374(3):462-468. PubMed ID: 32561684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
